Oncology and Carcinogenesis articles for Japan

Time frame: 1 May 2025 - 30 April 2026

View topic

Count: 258

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
2 1.93
High-Speed Atomic Force Microscopy Reveals Disordered Region-Mediated Structural Plasticity of Anaplastic Lymphoma Kinase Fusion Proteins Induced by Inhibitors 1.00
Harnessing Dye-Induced Local Heating in Lipid Membranes: A Path to Near-Infrared Light-Modulated Artificial Synaptic Vesicles 0.93
1 0.19
Allosteric DNA Nanorobots for Targeted Glioma Therapy: Acid‐Triggered Doxorubicin Delivery 0.19
5 3.28
Molecular Switching from Morule to Squamous Metaplasia via p40 and the EBP50/S100A4/Myosin 9 Axis in Endometrial Carcinoma 1.00
Bone Marrow Stromal Cell Antigen 2 Promotes Esophageal Squamous Cell Carcinoma Progression by Mediating the Cell-Cell Interaction between Cancer Cells and Cancer-Associated Fibroblasts 1.00
Increased Meflin expression in cancer-associated fibroblasts restrains tumor cell proliferation and shapes vessel-rich stroma in triple-negative breast cancer 1.00
Identification of a growth-promoting gene cluster in the region 2q24 as a driver of tumorigenesis in childhood hepatoblastoma 0.17
Transcription Factor YY2 inhibits tumor cell glutamine catabolism by regulating GLS1 RNA splicing isoform GAC 0.11
3 2.94
Correlation-Based Morphometric Analysis Reveals Structural Remodeling of Platelet-Bound Circulating Tumor Cells in Urothelial Carcinoma 1.00
Beyond the Nucleus: Cytoplasmic Dominance in Follicular Thyroid Carcinoma Detection Using Single-Cell Raman Imaging across Multiple Devices 0.94
Characterizing for Subcellular Physical Property Changes of Chemotherapy Drug-Resistant Malignant Cancer Cells 1.00
1 1.00
Programmable Antigen-Specific Immunity via Self-Adjuvanting Nanovaccines Co-Delivering Immune Modulators 1.00
11 7.01
Surgical Outcomes of Non-Benchmark Perihilar Cholangiocarcinoma: A Multicenter Study from High-Volume Centers in Japan. 1.00
Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. 1.00
Setting the Standard in Robotic Whipple Surgery: International Multicenter Benchmark Analysis. 0.15
Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar). 0.03
Robotic Versus Open and Laparoscopic Pancreaticoduodenectomy: A Nationwide Matched Study in Japan. 1.00
Tumor Serosal Invasion in Perihilar Cholangiocarcinoma: A Lethal But Overlooked Feature. 1.00
Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials. 0.45
International Validation of a Recurrence Risk Model for Stage II Colon Cancer: The SPHERE Study. 0.68
Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled Trial. 1.00
Effect of Double Layer Polyglycolic Acid Felt for Reducing Pancreatic Fistula After Pancreatoduodenectomy: Results of a Multicenter Randomized Control Trial (PLANET-PJ trial). 0.62
Recommendations on Perihilar Cholangiocarcinoma. The Milan Jury-Based Consensus. 0.08
4 1.15
Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability 0.03
Magrolimab plus azacitidine vs physician’s choice for untreated iTP53/i-mutated acute myeloid leukemia: the ENHANCE-2 study 0.05
The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NFκB signaling 0.08
Phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for Elderly Patients with Adult T-Cell Leukemia/Lymphoma 1.00
4 1.22
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements 0.07
Survival After Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma 0.45
Genomic and clinical parallels between US and Japanese gastric cancers: a propensity score-matched cohort study 0.25
Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials 0.45
1 0.05
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception 0.05
5 0.44
Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1 0.22
Genome-Wide CRISPR Screening Reveals that mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer 0.04
Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy 0.06
Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy 0.07
Perivascular Niche–Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan Treatment 0.04
1 0.01
Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction 0.01
1 0.25
Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy 0.25
1 1.00
Fabrication of a self-assembling peptide for the inhibition of cancer cell proliferation by targeting LAT1 1.00
1 1.00
Inhibition of ferroptosis by iN/i-oxide-based fluorescent probes ivia/i selective oxidation of ferrous ions 1.00
1 0.14
Cigarette smoking and long-term incidence of colorectal cancer subclassified by tumor-infiltrating myeloid cells: A prospective cohort study 0.14
2 1.05
Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial 1.00
Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study 0.05
2 0.19
Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial 0.14
An Exosome-Based Liquid Biopsy for the Detection of Early-Onset Colorectal Cancer: The ENCODER Multicenter Study 0.04
4 1.40
<atl>iTff2/i marks gastric corpus progenitors that give rise to pyloric metaplasia/SPEM following injury</atl> 0.21
Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study 0.16
Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy 0.03
Real-world impact of implementing lumen-apposing metal stents for pancreatic fluid collections: a nationwide Japanese study 1.00
3 1.08
NRF2-COX2-PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma. 0.96
Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling. 0.05
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. 0.07
1 0.11
On-Chip Dynamic Mechanical Characterization: from Cells to Nucleus* 0.11
3 1.20
Attributable fraction and interaction of tobacco smoking and alcohol drinking on the risk of head and neck cancer: a pooled analysis of 11 prospective cohort studies in Japan 1.00
The impact of an organized screening program on gastric cancer incidence: a quasi-experimental study 0.07
Maternal prenatal infection and childhood leukaemia: a Childhood Cancer and Leukemia International Consortium (CLIC) meta-analysis 0.13
1 0.38
Exosomal Liquid Biopsy for the Early Detection of Gastric Cancer 0.38
17 14.40
The tumor suppressor NDRG2 recruits protein phosphatase 2A to suppress STAT5 phosphorylation in adult T-cell leukemia/lymphoma 1.00
A novel synthetic melanin as a potential anticancer agent that induces apoptosis and cyclin D downregulation through distinct pathways 0.82
Targeting EphA2 under DNA damage causes mitotic bypass via p21 induction 1.00
A missense mutation in acyl-CoA synthetase ACSL4 reveals essential residues for catalytic activity in ferroptosis 1.00
Targeting the splicing factor CWC22 induces mitotic slippage through repression of BubR1 expression and CDK1 activity in cancer cells 1.00
PKM2 inhibitor suppresses kidney fibrogenesis by disrupting YAP-TEAD-CCN2 transcriptional signaling following ischemia–reperfusion injury 1.00
CAPN15 is a non-proteasomal, ubiquitin-directed calpain protease that regulates cell adhesion by cleaving E-cadherin 1.00
Chemical and biological characterization of glycidamide-adducted adenine in DNA 1.00
Dissecting stress-activated protein kinase (SAPK)–signaling pathways using multiplex gene knockout HeLa cells 1.00
The receptor tyrosine kinase ErbB2/HER2 governs CDK4 inhibitor sensitivity, timing and irreversibility of the G1/S transition 0.88
The proton-sensing OGR1 receptor and hypoxia-inducible factors promote metal ion-induced inflammatory responses in coronary artery smooth muscle cells 0.86
Loss of angulin-1/LSR promotes vasculogenic mimicry and epithelial-mesenchymal transition in breast cancer 1.00
Molecular basis of the autoregulatory mechanism of motor neuron-related splicing factor 30 1.00
Microcurrent stimulation induces cell death in p53-mutant and 5-FU-resistant breast cancer 1.00
The Ser7 phosphorylation of RNA polymerase II-CTD is required for the recruitment of E3 ubiquitin ligase Asr1 and subtelomeric gene silencing 0.22
Inhibitory effects of β-galactoside α2,6-sialyltransferase 1 on the Hippo pathway in breast cancer cells 0.13
SART1 uniquely localizes to spindle poles forming a SART1 cap and promotes spindle pole assembly 0.50
2 2.00
Initial evaluation of radioiodine therapy using Imaging for long-term prognosis in thyroid cancer: A retrospective study 1.00
Clinical Significance of Successful Ablation in Follicular Thyroid Carcinoma 1.00
7 2.13
Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLC 1.00
Targeting kinesin family member 20A sensitizes stem-like triple-negative breast cancer cells to standard chemotherapy 0.02
IFN-γ–driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy 0.05
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion 0.02
Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models 0.02
A distinct mechanism of epigenetic reprogramming silences PAX2 and initiates endometrial carcinogenesis 0.05
Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer 0.96
25 5.86
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. 0.09
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study. 0.01
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005. 0.04
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer. 0.18
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. 0.07
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer. 0.09
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2 0.06
Ifinatamab Deruxtecan in Patients With Extensive-Stage Small-Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Trial. 0.19
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study. 0.07
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. 0.32
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. 0.05
Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis (INSPiRED 006): An International, Multicenter Analysis. 0.04
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. 0.04
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial. 1.00
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas 0.07
Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial). 1.00
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. 0.16
Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study. 0.03
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. 0.11
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab. 0.08
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. 0.05
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study. 0.08
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial. 1.00
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer. 1.00
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database. 0.05
2 0.18
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma 0.08
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study 0.10
1 1.00
Klf5 Regulates the Transition from Apical Radial Glia to Intermediate Progenitor Cells in the Developing Mammalian Brain 1.00
2 1.07
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer 0.07
Clinical utility of the 5-point visual Deauville score for preoperative evaluation in stage I non–small cell lung cancer: A multicenter retrospective study 1.00
3 2.25
A Cascade-Responsive AND-Logic-Activatable Nanoprobe for Intraoperative Fluorescence Imaging of Colorectal Cancer 0.25
Photoaffinity Labeling Strategy Reveals Tetraspanin CD9 as a Transient Target of Anticancer Yaku’amide B 1.00
Optogenetic Cancer Therapy Using the Light-Driven Outward Proton Pump Rhodopsin Archaerhodopsin-3 (AR3) 1.00
3 0.66
Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials 0.45
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.18
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 0.03
3 1.45
BRCA2-dependent maturation of nascent strands during DNA replication 0.25
An interactome-based framework for DDB1- and CUL4-associated factor prioritization in targeted protein degradation 1.00
The E3 ligase RNF32 controls the IκB kinase complex and NF-κB signaling in intestinal stem cells 0.20
4 0.06
Evolutionary characterization of lung cancer metastasis 0.00
Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma 0.01
Somatic evolution following cancer treatment in normal tissue 0.00
Axonal injury is a targetable driver of glioblastoma progression 0.05
3 1.24
Designing protein-based artificial kinetochores as decoys to prevent meiotic errors in oocytes 1.00
NOX1 and NPY1R mark regional colon stem cell populations that serve as cancer origins in vivo 0.11
Evolutionarily conserved role of telomerase reverse transcriptase in programming the microenvironment via regulation of the cGAS–STING pathway 0.13
2 0.04
Highly specific intracellular ubiquitination of a small molecule 0.03
Tegavivint triggers TECR-dependent nonapoptotic cancer cell death 0.01
36 23.41
Immune-induced TCR-like antibodies regulate specific T cell response in mice 1.00
PD-1 antibody-bound progenitor-exhausted CD8+ T cells in lymph nodes boost PD-1-blockade anti-tumor immunity in gastrointestinal cancer 1.00
Ponatinib inhibits LCK and PI3K signaling and promotes CD8+ T stem cell memory cell development 1.00
Bleb-based extravasation uses conserved morphodynamics but divergent calcium control 0.88
Structural basis for prostaglandin and drug transport via SLCO2A1 0.18
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in G12C-mutant advanced solid tumors: a first-in-human study 0.11
Recruitment of BRD4 to the ASXL1 genomic targets depends on the extra-terminal domain of BRD4 0.06
Machine learning-predicted insulin resistance is a risk factor for 12 types of cancer 0.71
14-3-3ζ interacts with DNA-binding domain of FOXO3a and competitively dissociates DNA by dual-motif tethering 1.00
Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC 0.06
A role for condensin-mediator interaction in mitotic chromosome organization 0.54
CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting 0.95
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial 0.02
Ribosome biogenesis as a potential therapeutic target in KRAS mutant colorectal cancer 1.00
Structural dynamics of mixed-subunit CaMKIIα/β heterododecamers filmed by high-speed AFM 1.00
Thrombopoietin increases susceptibility for EVI1 + KMT2A-MLLT3-driven AML expressing stem cell genes linked to poor outcome 0.06
The molecular cartography of malignant and benign sebaceous tumours 0.13
Cancer-associated USP28 missense mutations disrupt 53BP1 interaction and p53 stabilization 1.00
Predictive models of melanoma metastasis based on dermatoscopy in an international retrospective human reader study 0.06
EP300 deficiency leads to chronic replication stress mediated by defective replication fork protection 0.05
Chromatin accessibility in stem cells unveils progressive transcriptional alterations in myelodysplastic syndrome 1.00
Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial 1.00
Targeting fibroblast derived thrombospondin 2 disrupts an immune-exclusionary environment at the tumor front in colorectal cancer 0.95
Mutation of CMTR2 in Lung Adenocarcinoma Alters RNA Alternative Splicing and Reveals Therapeutic Vulnerabilities 1.00
Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma 0.05
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy 0.50
Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies 0.14
Structural insights into Wnt/β-catenin signaling regulation by LGR4, R-spondin, and ZNRF3 1.00
Regulatory role of the N-terminal intrinsically disordered region of the DEAD-box RNA helicase DDX3X in selective RNA recognition 1.00
Clonal diversity shapes the tumour microenvironment leading to distinct immunotherapy responses in metastatic urothelial carcinoma 1.00
ALS/FTD-linked TBK1 deficiency in microglia induces an aged-like microglial signature and drives social recognition deficits in mice 0.05
Multi-omics analysis identifies an M-MDSC-like immunosuppressive phenotype in lineage-switched AML with rearrangement 0.95
Functional interplay between condensin I and topoisomerase Iiα in single-molecule DNA compaction 1.00
p53-inducible lncRNA LOC644656 causes genotoxic stress-induced stem cell maldifferentiation and cancer chemoresistance 1.00
Direct evaluation of antiplatelet therapy in coronary artery disease by comprehensive image-based profiling of circulating platelets 0.98
Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma 1.00
5 0.21
Global multi-ancestry genome-wide analyses identify genes and biological pathways associated with thyroid cancer and benign thyroid diseases 0.03
Genomic evolution of pancreatic cancer at single-cell resolution 0.03
De novo and inherited dominant variants in U4 and U6 snRNA genes cause retinitis pigmentosa 0.05
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation 0.05
Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics 0.05
2 1.00
Purine salvage pathway protects CD8 T cells from metabolic stress 0.97
The transcription complex p52–ETS1 is essential for germinal center formation 0.03
11 0.85
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial 0.16
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial 0.04
Global and regional cancer burden attributable to modifiable risk factors to inform prevention 0.07
Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade 0.03
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial 0.16
Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results 0.03
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial 0.11
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial 0.04
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial 0.08
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial 0.10
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer 0.03
1 0.11
Brain tumors induce widespread disruption of calvarial bone and alteration of skull marrow immune landscape 0.11
2 1.09
Spatial colocalization and molecular crosstalk of myofibroblastic CAFs and tumor cells shape lymph node metastasis in oral squamous cell carcinoma 0.79
Systematically identification of survival-associated eQTLs in a Japanese kidney cancer cohort 0.30
1 0.11
Long-term outcomes after unilateral salpingo-oophorectomy: A registry-based retrospective cohort study 0.11
13 8.35
CD28-driven ex vivo generation of stem-like memory CD8+ T cells bypassing CD3/TCR signaling 0.05
Sister chromatid separation determines the proliferative properties upon whole-genome duplication via homologous chromosome arrangement 1.00
Alternative microexon splicing code for a four-amino acid peptide of PTPRD governs behavioral development 1.00
Switching of the c-Myc protein degradation pathway depending on the PP2A-B55α complex levels 1.00
Oncogenic function and transcriptional dynamics of MYCN in liver tumorigenesis 0.88
Genomic and transcriptomic landscape of carcinogenesis in patients with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) 1.00
Mutant p53 regulates cancer cell invasion in complex three-dimensional environments through mevalonate pathway–dependent Rho/ROCK signaling 0.08
Genetic dissection of nonconventional introns reveals codominant noncanonical splicing code in Euglena 0.97
The activity and expression of adenylosuccinate lyase were reduced during modern human evolution, affecting brain and behavior 0.50
Neutron and time-resolved X-ray crystallography reveal the substrate recognition and catalytic mechanism of human Nudix hydrolase MTH1 0.82
Tumor-promoting UBR4 coordinates impaired mitophagy–associated senescence and lung adenocarcinoma pathogenesis 0.08
Epithelial Regnase-1 inhibits colorectal tumor growth by regulating IL-17 signaling via degradation of NFKBIZ mRNA 0.93
Mutant IDH1 cooperates with NPM1c or FLT3ITD to drive distinct myeloid diseases and molecular outcomes 0.03
1 0.09
Mesorectal Fascia Involvement by Tumor Deposits or Extramural Vascular Invasion at MRI Predicts Prognosis in Rectal Cancer. 0.09
2 0.88
AQP5: A functional gastric cancer stem cell marker in mouse and human tumors 0.06
Nematode telomerase RNA hitchhikes on introns of germline–up-regulated genes 0.82
5 2.02
Mesothelial cells promote peritoneal invasion and metastasis of ascites-derived ovarian cancer cells through spheroid formation 0.88
Caspase-2 deficiency drives pathogenic liver polyploidy and increases age-associated hepatocellular carcinoma in mice 0.07
Functional landscape of mechanistic diversity in 27 claudin family members at tight junctions 1.00
Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma–GATA3 molecular subgroup 0.03
CD8+ T cell–derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells 0.04
2 1.98
On-demand GLUT3 expression augments CAR T cell metabolic fitness and antitumor efficacy in preclinical models of glioblastoma 1.00
Cationic nanogel–based nasal therapeutic HPV vaccine prevents the development of cervical cancer 0.98
5 3.20
Dual pathways via CENP-C and Mis18C recruit HJURP for CENP-A deposition into vertebrate centromeres 1.00
Polyubiquitin architecture editing on collided ribosomes maintains persistent RQC activity. 1.00
Nucleosome interaction of the CPC secures centromeric chromatin integrity and chromosome segregation fidelity 0.13
Targeting myoferlin in ER/Golgi vesicle trafficking reprograms pancreatic cancer-associated fibroblasts. 0.07
MPS1 promotes timely spindle bipolarization to prevent kinetochore-microtubule attachment errors in oocytes. 1.00
5 0.35
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial 0.12
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study 0.05
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial 0.07
13 3.09
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial 0.50
Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial 0.09
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial 0.04
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial 0.03
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial 0.08
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study 1.00
Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study 0.11
Health-related quality of life in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial 0.11
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial 0.02
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial 1.00
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial 0.05
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study 0.04
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study 0.02
21 1.45
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.08
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer 0.19
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer 0.04
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer 0.05
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer 0.03
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 0.02
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab 0.09
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer 0.10
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer 0.03
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer 0.06
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.07
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC 0.14
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC 0.04
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer 0.09
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy 0.04
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer 0.11
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy 0.04
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer 0.04
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer 0.11
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer 0.04
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer 0.05
1 1.00
Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: a nationwide population-based study 1.00

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.